Found: 359
Select item for more details and to access through your institution.
Treatment options for thalassemia patients with osteoporosis.
- Published in:
- Annals of the New York Academy of Sciences, 2010, v. 1202, n. 1, p. 237, doi. 10.1111/j.1749-6632.2010.05542.x
- By:
- Publication type:
- Article
Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine.
- Published in:
- Clinical & Experimental Medicine, 2022, v. 22, n. 2, p. 319, doi. 10.1007/s10238-021-00746-4
- By:
- Publication type:
- Article
Emerging treatment strategies for COVID-19 infection.
- Published in:
- Clinical & Experimental Medicine, 2021, v. 21, n. 2, p. 167, doi. 10.1007/s10238-020-00671-y
- By:
- Publication type:
- Article
Organ-specific manifestations of COVID-19 infection.
- Published in:
- Clinical & Experimental Medicine, 2020, v. 20, n. 4, p. 493, doi. 10.1007/s10238-020-00648-x
- By:
- Publication type:
- Article
Belantamab mafodotin, lenalidomide, and dexamethasone in transplant‐ineligible patients with newly diagnosed multiple myeloma: Analysis of belantamab mafodotin‐associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1/2 study
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 3, p. 502, doi. 10.1002/ajh.27219
- By:
- Publication type:
- Article
Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA.
- Published in:
- American Journal of Hematology, 2024, v. 99, n. 3, p. 396, doi. 10.1002/ajh.27206
- By:
- Publication type:
- Article
Prospective phase 2 trial of daratumumab with dexamethasone in patients with relapsed/refractory multiple myeloma and severe renal impairment or on dialysis: The DARE study.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 9, p. E226, doi. 10.1002/ajh.27001
- By:
- Publication type:
- Article
XBB.1.5 neutralizing antibodies upon bivalent COVID‐19 vaccination are similar to XBB but lower than BQ.1.1.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 5, p. E123, doi. 10.1002/ajh.26887
- By:
- Publication type:
- Article
Belantamab mafodotin induces immunogenic cell death within 24 h post‐administration in newly diagnosed multiple myeloma patients.
- Published in:
- American Journal of Hematology, 2023, v. 98, n. 3, p. E65, doi. 10.1002/ajh.26823
- By:
- Publication type:
- Article
SARS‐CoV‐2 humoral responses following booster BNT162b2 vaccination in patients with B‐cell malignancies.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 10, p. 1300, doi. 10.1002/ajh.26669
- By:
- Publication type:
- Article
Chromosome 1q21 aberrations identify ultra high‐risk myeloma with prognostic and clinical implications.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 9, p. 1142, doi. 10.1002/ajh.26639
- By:
- Publication type:
- Article
Health‐related quality of life in patients with relapsed/refractory multiple myeloma treated with pomalidomide and dexamethasone ± subcutaneous daratumumab: Patient‐reported outcomes from the APOLLO trial.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 4, p. 481, doi. 10.1002/ajh.26480
- By:
- Publication type:
- Article
Third dose of the BNT162b2 vaccine results in very high levels of neutralizing antibodies against SARS‐CoV‐2: Results of a prospective study in 150 health professionals in Greece.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 4, p. E147, doi. 10.1002/ajh.26468
- By:
- Publication type:
- Article
Kinetics of anti‐SARS‐CoV‐2 neutralizing antibodies development after BNT162b2 vaccination in patients with amyloidosis and the impact of therapy.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 1, p. E27, doi. 10.1002/ajh.26406
- By:
- Publication type:
- Article
Late‐onset hematological complications post COVID‐19: An emerging medical problem for the hematologist.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 1, p. 119, doi. 10.1002/ajh.26384
- By:
- Publication type:
- Article
Distinct neutralization profile of spike variants by antibodies induced upon SARS‐CoV‐2 infection or vaccination.
- Published in:
- American Journal of Hematology, 2022, v. 97, n. 1, p. E3, doi. 10.1002/ajh.26380
- By:
- Publication type:
- Article
Comparison of neutralizing antibody responses against SARS‐CoV‐2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZD1222 vaccine dose be given earlier?
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 9, p. E321, doi. 10.1002/ajh.26248
- By:
- Publication type:
- Article
Covid‐19 vaccination in patients with multiple myeloma: Focus on immune response.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 8, p. 896, doi. 10.1002/ajh.26263
- By:
- Publication type:
- Article
Age‐dependent and gender‐dependent antibody responses against SARS‐CoV‐2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine.
- Published in:
- American Journal of Hematology, 2021, v. 96, n. 7, p. E257, doi. 10.1002/ajh.26185
- By:
- Publication type:
- Article
Hematological findings and complications of COVID‐19.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 7, p. 834, doi. 10.1002/ajh.25829
- By:
- Publication type:
- Article
Cell‐free DNA analysis for the detection of MYD88 and CXCR4 mutations in IgM monoclonal gammopathies; an update with clinicopathological correlations.
- Published in:
- American Journal of Hematology, 2020, v. 95, n. 6, p. E148, doi. 10.1002/ajh.25802
- By:
- Publication type:
- Article
Bone marrow biopsy in low‐risk monoclonal gammopathy of undetermined significance reveals a novel smoldering multiple myeloma risk group.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 5, p. E146, doi. 10.1002/ajh.25441
- By:
- Publication type:
- Article
Consolidation therapy with the combination of bortezomib and lenalidomide (VR) without dexamethasone in multiple myeloma patients after transplant: Effects on survival and bone outcomes in the absence of bisphosphonates.
- Published in:
- American Journal of Hematology, 2019, v. 94, n. 4, p. 400, doi. 10.1002/ajh.25392
- By:
- Publication type:
- Article
Renal outcomes in patients with AL amyloidosis: Prognostic factors, renal response and the impact of therapy.
- Published in:
- American Journal of Hematology, 2017, v. 92, n. 7, p. 632, doi. 10.1002/ajh.24738
- By:
- Publication type:
- Article
An international, multicenter, prospective, observational study of neutropenia in patients being treated with lenalidomide + dexamethasone for relapsed or relapsed/refractory multiple myeloma (RR-MM).
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 8, p. 806, doi. 10.1002/ajh.24416
- By:
- Publication type:
- Article
Bortezomib-based triplets are associated with a high probability of dialysis independence and rapid renal recovery in newly diagnosed myeloma patients with severe renal failure or those requiring dialysis.
- Published in:
- American Journal of Hematology, 2016, v. 91, n. 5, p. 499, doi. 10.1002/ajh.24335
- By:
- Publication type:
- Article
Long-term outcomes of primary systemic light chain (AL) amyloidosis in patients treated upfront with bortezomib or lenalidomide and the importance of risk adapted strategies.
- Published in:
- American Journal of Hematology, 2015, v. 90, n. 4, p. E60, doi. 10.1002/ajh.23936
- By:
- Publication type:
- Article
Clinical features, outcome, and prognostic factors for survival and evolution to multiple myeloma of solitary plasmacytomas: A report of the Greek myeloma study group in 97 patients.
- Published in:
- American Journal of Hematology, 2014, v. 89, n. 8, p. 803, doi. 10.1002/ajh.23745
- By:
- Publication type:
- Article
Treatment with bortezomib-based regimens improves overall response and predicts for survival in patients with primary or secondary plasma cell leukemia: Analysis of the Greek myeloma study group.
- Published in:
- American Journal of Hematology, 2014, v. 89, n. 2, p. 145, doi. 10.1002/ajh.23600
- By:
- Publication type:
- Article
The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed/refractory multiple myeloma but has no effect on bone formation: Final results on 205 patients of the Greek myeloma study group.
- Published in:
- American Journal of Hematology, 2014, v. 89, n. 1, p. 34, doi. 10.1002/ajh.23577
- By:
- Publication type:
- Article
Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens.
- Published in:
- American Journal of Hematology, 2013, v. 88, n. 9, p. 765, doi. 10.1002/ajh.23504
- By:
- Publication type:
- Article
Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: A single center experience on 228 patients.
- Published in:
- American Journal of Hematology, 2012, v. 87, n. 9, p. 861, doi. 10.1002/ajh.23258
- By:
- Publication type:
- Article
Increased expression of cyclin-D1 on trephine bone marrow biopsies independently predicts for shorter overall survival in patients with multiple myeloma treated with novel agents.
- Published in:
- American Journal of Hematology, 2012, v. 87, n. 7, p. 734, doi. 10.1002/ajh.23223
- By:
- Publication type:
- Article
Tumor-primed natural killer cells from patients with multiple myeloma lyse autologous, NK-resistant, bone marrow-derived malignant plasma cells.
- Published in:
- American Journal of Hematology, 2011, v. 86, n. 12, p. 967, doi. 10.1002/ajh.22163
- By:
- Publication type:
- Article
Lenalidomide-associated pneumonitis in patients with plasma cell dyscrasias.
- Published in:
- American Journal of Hematology, 2011, v. 86, n. 10, p. 882, doi. 10.1002/ajh.22135
- By:
- Publication type:
- Article
Prophylactic antibiotics for the prevention of neutropenic fever in patients undergoing autologous stem-cell transplantation: Results of a single institution, randomized phase 2 trial.
- Published in:
- American Journal of Hematology, 2010, v. 85, n. 11, p. 863, doi. 10.1002/ajh.21855
- By:
- Publication type:
- Article
Impfempfehlungen beim Multiplen Myelom: ein Konsensbericht des European Myeloma Network.
- Published in:
- Kompass Onkologie, 2022, v. 9, n. 1, p. 3, doi. 10.1159/000522451
- By:
- Publication type:
- Article
Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone with or Without Radiotherapy in Primary Mediastinal Large B-Cell Lymphoma: The Emerging Standard of Care.
- Published in:
- Oncologist, 2012, v. 17, n. 2, p. 239, doi. 10.1634/theoncologist.2011-0275
- By:
- Publication type:
- Article
Robust Neutralizing Antibody Responses 6 Months Post Vaccination with BNT162b2: A Prospective Study in 308 Healthy Individuals.
- Published in:
- Life (2075-1729), 2021, v. 11, n. 10, p. 1077, doi. 10.3390/life11101077
- By:
- Publication type:
- Article
Seroprevalence of Antibodies against SARS-CoV-2 among the Personnel and Students of the National and Kapodistrian University of Athens, Greece: A Preliminary Report.
- Published in:
- Life (2075-1729), 2020, v. 10, n. 9, p. 214, doi. 10.3390/life10090214
- By:
- Publication type:
- Article
Differences in the immunoglobulin gene repertoires of IgG versus IgA multiple myeloma allude to distinct immunopathogenetic trajectories.
- Published in:
- Frontiers in Oncology, 2023, v. 13, p. 1, doi. 10.3389/fonc.2023.1123029
- By:
- Publication type:
- Article
Pomalidomide- and dexamethasone-based regimens in the treatment of refractory/relapsed multiple myeloma.
- Published in:
- Therapeutic Advances in Hematology, 2022, v. 13, p. 1, doi. 10.1177/20406207221090089
- By:
- Publication type:
- Article
An overview of treatment options for patients with relapsed/refractory multiple myeloma and renal impairment.
- Published in:
- Therapeutic Advances in Hematology, 2022, v. 13, p. 1, doi. 10.1177/20406207221088458
- By:
- Publication type:
- Article
Does the Simultaneous Introduction of Several Pharmaceuticals in the Post-Lenalidomide Era Translate to Better Outcomes in Relapse Refractory Multiple Myeloma? Findings from the Real-World Innovation in Multiple Myeloma (REAL IMM) Study.
- Published in:
- Cancers, 2023, v. 15, n. 24, p. 5846, doi. 10.3390/cancers15245846
- By:
- Publication type:
- Article
The Role of t(11;14) in Tailoring Treatment Decisions in Multiple Myeloma.
- Published in:
- Cancers, 2023, v. 15, n. 24, p. 5829, doi. 10.3390/cancers15245829
- By:
- Publication type:
- Article
Adult Patients with Cancer Have Impaired Humoral Responses to Complete and Booster COVID-19 Vaccination, Especially Those with Hematologic Cancer on Active Treatment: A Systematic Review and Meta-Analysis.
- Published in:
- Cancers, 2023, v. 15, n. 8, p. 2266, doi. 10.3390/cancers15082266
- By:
- Publication type:
- Article
Low Spike Antibody Levels and Impaired BA.4/5 Neutralization in Patients with Multiple Myeloma or Waldenstrom's Macroglobulinemia after BNT162b2 Booster Vaccination.
- Published in:
- Cancers, 2022, v. 14, n. 23, p. 5816, doi. 10.3390/cancers14235816
- By:
- Publication type:
- Article
Real-World Use and Effectiveness of Carfilzomib Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma in Europe.
- Published in:
- Cancers, 2022, v. 14, n. 21, p. 5311, doi. 10.3390/cancers14215311
- By:
- Publication type:
- Article
SARS-CoV-2 Neutralizing Antibodies Kinetics Postvaccination in Cancer Patients under Treatment with Immune Checkpoint Inhibition.
- Published in:
- Cancers, 2022, v. 14, n. 11, p. 2796, doi. 10.3390/cancers14112796
- By:
- Publication type:
- Article
Daratumumab Improves Bone Turnover in Relapsed/Refractory Multiple Myeloma; Phase 2 Study "REBUILD".
- Published in:
- Cancers, 2022, v. 14, n. 11, p. 2768, doi. 10.3390/cancers14112768
- By:
- Publication type:
- Article